Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Sichuan Honghe Biotechnology Co., Ltd.
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07138001CT.gov Phase 2 Clinical Trial of KH617 | — | Not Yet Recruiting | — | — | — |
NCT05694416CT.gov Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma | — | Unknown | — | — | — |
NCT05106296CT.gov Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | — | Recruiting | — | — | — |
NCT04135807CT.gov Implantable Microdevice In Primary Brain Tumors | — | Recruiting | — | — | — |
NCT04049669CT.gov Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | — | Active Not Recruiting | — | — | — |
NCT06105619CT.gov A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). | — | Active Not Recruiting | — | — | — |
NCT02502708CT.gov Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | — | Completed | — | — | — |
NCT00613028CT.gov Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | — | Completed | — | — | — |
NCT00613223CT.gov Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | — | Completed | — | — | — |
NCT00612430CT.gov Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Etoposide (this asset) | Sichuan Honghe Biotechnology Co., Ltd. | P2/3 | BB · 64 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Etoposide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Megakaryoblastic Leukemia | — | P3 | BBB · 79 |
| Acute Monocytic Leukemia | — | P3 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Etoposide in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/etoposide-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →